Business Context and Reporting Period
Company: Aquinox Pharmaceuticals, Inc. (Note: Request metadata listed "Neurogene Inc.", but the filing text identifies the registrant as Aquinox Pharmaceuticals, Inc.)
Filing Type: Form 8-K (Current Report)
Date: August 6, 2015
Subject: Regulation FD Disclosure regarding clinical trial results for the investigational drug AQX-1125.
Key Financial Metrics
This filing is a current report regarding clinical trial data and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Results
The Company reported top-line results from the LEADERSHIP trial on June 25, 2015, with further analysis announced on August 6, 2015. Key findings include:
- Primary Endpoint: Did not reach statistical significance.
- Pain Reduction Trend: Encouraging trend observed for patients treated with AQX-1125 compared to placebo.
- Clinically Meaningful Improvement: 49% of patients on AQX-1125 achieved a 2-point or greater improvement on the 11-point NRS scale, compared to 39% on placebo.
- Secondary Endpoints (Positive Results):
- Statistically significant 1.3-point greater reduction over placebo on maximum daily pain at six weeks (p = 0.030).
- Statistically significant 4.4-point greater reduction over placebo on the O'Leary Sant Symptom Scale at six weeks (p = 0.008).
Outlook and Management Commentary
Management stated that the positive results from the secondary endpoints support the further development of AQX-1125 for Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC). The Company held a conference call and live webcast on August 6, 2015, accompanied by an investor presentation (Exhibit 99.1).
Investor Verification Checklist
- Verify the discrepancy between the request metadata ("Neurogene Inc.") and the filing registrant ("Aquinox Pharmaceuticals, Inc.").
- Review the attached Exhibit 99.1 (Investor Presentation) for detailed statistical data and future development timelines.
- Confirm the specific regulatory pathway and next steps for AQX-1125 following the mixed primary endpoint results.
- Check subsequent filings for any financial impact or capital raise requirements resulting from the decision to continue development.